Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments: Protein Sciences, offering biological reagents, proteomic analytical tools, and automated western blot and ELISA workflow solutions; and Diagnostics and Spatial Biology, producing diagnostic products, exosome-based molecular diagnostic assays, in-situ hybridization assays, and spatial genomic instrumentation.
Headquartered in Minneapolis, Minnesota, Bio-Techne operates globally across North America, Europe, and Asia, manufacturing at multiple facilities in those regions. The company pursues growth through targeted acquisitions, including Lunaphore SA (fiscal 2024) and an investment in Spear Bio (fiscal 2025). It holds a 19.9% stake in Wilson Wolf Corporation, with full acquisition planned by the end of calendar 2027.
US 56% · EMEAExcluding UK 22% · CN 8% · APACExcluding Greater China 6% · …
geographic · FY2025 (ended Jun 2025) · share of tagged segment revenue (10-K XBRL, as filed)
